| Title: | Impact of Allergic Rhinitis and Asthma on COVID-19 Infection, Hospitalization, and Mortality |
| Journal: | The Journal of Allergy and Clinical Immunology In Practice |
| Published: | 30 Oct 2021 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/34728408/ |
| DOI: | https://doi.org/10.1016/j.jaip.2021.10.049 |
| URL: | http://www.jaci-inpractice.org/article/S2213219821012022/pdf |
Publication 13808
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BACKGROUND: It remains unclear if patients with allergic rhinitis (AR) and/or asthma are susceptible to corona virus disease 2019 (COVID-19) infection, severity, and mortality.</p>
OBJECTIVE: To investigate the role of AR and/or asthma in COVID-19 infection, severity, and mortality, and assess whether long-term AR and/or asthma medications affected the outcomes of COVID-19.</p>
METHODS: Demographic and clinical data of 70,557 adult participants completed SARS-CoV-2 testing between March 16 and December 31, 2020, in the UK Biobank were analyzed. The rates of COVID-19 infection, hospitalization, and mortality in relation to pre-existing AR and/or asthma were assessed based on adjusted generalized linear models. We further analyzed the impact of long-term AR and/or asthma medications on the risk of COVID-19 hospitalization and mortality.</p>
RESULTS: Patients with AR of all ages had lower positive rates of SARS-CoV-2 tests (relative risk [RR]: 0.75, 95% confidence interval [CI]: 0.69-0.81, P < .001), with lower susceptibility in males (RR: 0.74, 95% CI: 0.65-0.85, P < .001) than females (RR: 0.8, 95% CI: 0.72-0.9, P < .001). However, similar effects of asthma against COVID-19 hospitalization were only major in participants aged <65 (RR: 0.93, 95% CI: 0.86-1, P = .044) instead of elderlies. In contrast, patients with asthma tested positively had higher risk of hospitalization (RR: 1.42, 95% CI: 1.32-1.54, P < .001). Neither AR nor asthma had an impact on COVID-19 mortality. None of conventional medications for AR or asthma, for example, antihistamines, corticosteroids, or β2 adrenoceptor agonists, showed association with COVID-19 infection or severity.</p>
CONCLUSION: AR (all ages) and asthma (aged <65) act as protective factors against COVID-19 infection, whereas asthma increases risk for COVID-19 hospitalization. None of the long-term medications had a significant association with infection, severity, and mortality of COVID-19 among patients with AR and/or asthma.</p>
10 Keywords
- Adult
- Asthma
- COVID-19
- COVID-19 Testing
- Female
- Hospitalization
- Humans
- Male
- Rhinitis, Allergic
- SARS-CoV-2
20 Authors
- Jianjun Ren
- Wendu Pang
- Yaxin Luo
- Danni Cheng
- Ke Qiu
- Yufang Rao
- Yongbo Zheng
- Yijun Dong
- Jiajia Peng
- Yao Hu
- Zhiye Ying
- Haopeng Yu
- Xiaoxi Zeng
- Zhiyong Zong
- Geoffrey Liu
- Deyun Wang
- Gang Wang
- Wei Zhang
- Wei Xu
- Yu Zhao
1 Application
| Application ID | Title |
|---|---|
| 69718 | Multi-omic analyses of otorhinolaryngology-related disorders |
Enabling scientific discoveries that improve human health